Each year, a huge number of new cases accounts of TB with added problems due to multidrug resistant TB varieties. Globally, TB is one of the top causes of loss of life among people living with HIV who are more likely than others to get TB infection. Current TB treatment includes long term administration of cocktail of drugs; hence, the development of an alternative armamentarium against TB is the primary requirement. In fact, new drugs with novel activity against mycobacteria are of significant importance in order to combat existing levels of resistance. The present report covers the discovery of a diarylquinoline TB drug, bedaquiline, its antituberculosis effects and mode of action. Clinical studies conducted on bedaquiline which brought it to the accelerated FDA acceptance have been described. This report is of great attention for therapeutic apothecaries working in TB medication growth in terms of creating further diarylquinoline applicants with a wide variety of antimycobacterial results.
Keywords: Antituberculosis drug, bedaquiniline, clinical trials, docking, diarylquinolone, Mycobacterium tuberculosis.
Population Pharmacokinetics and its Role in Anti-Tuberculosis Drug Development and Optimization of Treatment
Current Pharmaceutical Design New Tuberculostatic Agents Targeting Nucleic Acid Biosynthesis: Drug Design using QSAR Approaches
Current Pharmaceutical Design Enhanced Killing of Intracellular Pathogenic Bacteria by Phenothiazines and the Role of K+ Efflux Pumps of the Bacterium and the Killing Macrophage
Anti-Infective Agents in Medicinal Chemistry Synthesis of Coumarin-benzotriazole Hybrids and Evaluation of their Anti-tubercular Activity
Letters in Organic Chemistry Synthesis and Characterization of 1-carboxyphenothiazine Derivatives Bearing Nitrogen Mustard as Promising Class of Antitubercular Agents
Letters in Drug Design & Discovery Antimycobacterial Activities of Oxazolidinones: A Review
Infectious Disorders - Drug Targets New Anti-Tuberculosis Drugs in Clinical Development: An Overview
Current Bioactive Compounds Editorial from Guest Editor (Thematic Issue: Tuberculosis: Recent Advances in Our Understanding and Management)
Current Respiratory Medicine Reviews The Role of Surrogate Markers in the Clinical Evaluation of Antituberculous Chemotherapy
Current Medicinal Chemistry - Anti-Infective Agents Spoligotyping for Identification of Pulmonary Tuberculosis with Type 2 Diabetes Mellitus Profiles in Warangal, T.S.
Anti-Infective Agents TLC Bioautography on Screening of Bioactive Natural Products: An Update Review
Current Analytical Chemistry Social Leverage of Intellectual Property: Road to the Development of Better Therapy for Tuberculosis
Recent Patents on Anti-Infective Drug Discovery Heterocyclic N-oxides - A Promising Class of Agents against Tuberculosis, Malaria and Neglected Tropical Diseases
Current Pharmaceutical Design Isonicotinic Acid Hydrazide Derivatives: Synthesis, Antimycobacterial, Antiviral, Antimicrobial Activity and QSAR Studies
Letters in Drug Design & Discovery Drug Susceptibility of the Mycobacterium Genus: In Vitro Tests and Clinical Implications
Current Clinical Pharmacology Alkaloids as Important Scaffolds in Therapeutic Drugs for the Treatments of Cancer, Tuberculosis, and Smoking Cessation
Current Topics in Medicinal Chemistry Synthesis and Antimycobacterial Activity of Highly Functionalised Pyrrolothiazole Derivatives
Letters in Drug Design & Discovery Chorismate Synthase: An Attractive Target For Drug Development Against Orphan Diseases
Current Drug Targets Computational Determination of the Effects of Bacteriophage Bacteriophage Interactions in Human Body
Recent Patents on Biotechnology Pleural Fluid Analysis for Evaluating Pleural Effusions
Current Respiratory Medicine Reviews